DR. MICHAEL THOMAS NAPIERKOWSKI, M.D.

LONE TREE, CO

Research Active
Surgery NPI registered 21+ years 4 publications 2020 – 2025 NPI: 1396740858
Cell Line, TumorCell ProliferationAntineoplastic AgentsOxidative StressApoptosisStructure-Activity RelationshipMolecular StructureChromatography, High Pressure LiquidCell SurvivalLiposomesGlutathioneSolubilitySulfhydryl CompoundsGlutathione PeroxidaseGlutathione Peroxidase GPX1

Practice Location

10240 PARK MEADOWS DR
LONE TREE, CO 80124-5425

Phone: (303) 338-4545

What does MICHAEL NAPIERKOWSKI research?

Dr. Napierkowski studies pentathiepins, unique compounds that have shown promise in cancer treatment. He looks at how these substances can be modified, using techniques like liposomal formulation, to make them more effective against cancer. His research examines how pentathiepins interact with cancer cells and helps to understand their biological effects. By inhibiting specific proteins that help cancer cells survive, his findings aim to introduce new and improved options for cancer therapies.

Key findings

  • Pentathiepins were found to be 15 times more effective than the best-known inhibitor of glutathione peroxidase 1 (GPx1), leading to significant oxidative stress and cell death in cancer cells.
  • Using liposomes increased pentathiepin's solubility by 400 times and stability fourfold in the presence of glutathione, while preserving its ability to fight cancer cells.
  • All six types of pentathiepins tested were effective at killing cancer cells and stopping their growth, with five of them strongly inhibiting the GPx1 protein.

Frequently asked questions

Does Dr. Napierkowski study cancer?
Yes, Dr. Napierkowski focuses on cancer research, specifically exploring new treatments using pentathiepins.
What treatments has Dr. Napierkowski researched?
He has researched pentathiepins as a potential class of drugs that can effectively kill cancer cells and inhibit survival mechanisms.
Is Dr. Napierkowski's work relevant to patients undergoing cancer treatment?
Absolutely. His research aims to improve cancer treatments, offering new options that could be more effective for patients.

Publications in plain English

Structure-activity-relationships of the Stability of Six Pentathiepins Towards Glutathione: Possible Correlations with Biological Activities.

2025

ChemMedChem

Napierkowski M, Schöne T, Bandaru SSM, Judernatz J, Schulig L +3 more

Plain English
This study looked at how stable six different types of pentathiepins are when exposed to a substance called glutathione, which is important for cell function. Researchers found that the stability of these compounds varied significantly based on their design, which in turn affected their ability to kill cancer cells; for instance, one type was much more effective under low glutathione conditions. This research helps us understand how pentathiepins might be better used in cancer treatments. Who this helps: Patients with cancer.

PubMed

Liposomal formulation of model pentathiepin improves solubility and stability toward glutathione while preserving anticancer activity.

2023

Archiv der Pharmazie

Napierkowski M, Janke U, Rong A, Delcea M, Bandaru SSM +2 more

Plain English
This study looked at how a special formulation using liposomes can make a cancer-fighting drug called pentathiepin easier to dissolve and more stable in the presence of a natural antioxidant called glutathione. Researchers found that using liposomes increased the drug's solubility significantly — by about 400 times — and made it four times more stable when exposed to glutathione, all while keeping its effectiveness against cancer cells intact. This matters because it could lead to more effective cancer treatments by overcoming challenges related to drug delivery. Who this helps: Patients undergoing cancer treatment.

PubMed

Comprehensive Evaluation of Biological Effects of Pentathiepins on Various Human Cancer Cell Lines and Insights into Their Mode of Action.

2021

International journal of molecular sciences

Wolff L, Bandaru SSM, Eger E, Lam HN, Napierkowski M +3 more

Plain English
This study looked at new compounds called pentathiepins and how they affect different human cancer cells. Researchers found that all six types of pentathiepins were effective at killing cancer cells and stopping their growth, with five of them also strongly inhibiting a specific protein (GPx1) involved in cell protection. This is important because the compounds create oxidative stress that damages DNA in cancer cells, leading them to die, which could improve cancer treatments in the future. Who this helps: This research benefits cancer patients and doctors looking for new treatment options.

PubMed

Pentathiepins: A Novel Class of Glutathione Peroxidase 1 Inhibitors that Induce Oxidative Stress, Loss of Mitochondrial Membrane Potential and Apoptosis in Human Cancer Cells.

2020

ChemMedChem

Behnisch-Cornwell S, Bandaru SSM, Napierkowski M, Wolff L, Zubair M +4 more

Plain English
This study examined a new group of compounds called pentathiepins, which can inhibit an enzyme called glutathione peroxidase 1 (GPx1) that helps cancer cells survive. Researchers found that these pentathiepins are about 15 times more effective than the currently best-known GPx1 inhibitor, and they can kill various human cancer cells by causing oxidative stress and cell death. The findings are important because they reveal a potential new way to target cancer cells and suggest that pentathiepins could be developed into effective cancer treatments. Who this helps: This helps cancer patients looking for new treatment options.

PubMed

Frequent Co-Authors

Carola Schulzke Patrick J Bednarski Siva Sankar Murthy Bandaru Lisa Wolff Tom Schöne Jo Judernatz Lukas Schulig Louis Schmidt Una Janke Alena Rong

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.